Authors
Kirema Garcia-Reyes, William H Wang, Mufiza Farid-Kapadia, Nehemiah Kebede, Dex L Underwood, Ling Cai, Heide A Stirnadel-Farrant, Cindy Wang, Neehar D Parikh
Published in
Hepatic oncology. Volume 13. Issue 1. Pages 2736861. Epub Oct 19, 2026.
Abstract
To describe treatment patterns and outcomes in patients with unresectable hepatocellular carcinoma (uHCC) treated with embolization.
This retrospective observational study used Optum's de-identified Market Clarity Data. US adults with HCC treated with embolization between July 2016-September 2022 were followed from first embolization following diagnosis until death and end of enrollment or study period.
Of 1,458 patients, 41.9%, 33.5%, and 24.6% received transarterial radioembolization (TARE), transarterial chemoembolization (TACE), and transarterial embolization (TAE), respectively, as initial embolization therapy; TARE use increased over time. Most were male (74.6%), white (66.5%), with a median age at index of 65.0 years, and 63.1% required ≥1 subsequent treatment (median treatment pattern follow-up: 16.3 months). Median (95% CI) time to first follow-up treatment or death was 5.9 (5.5-6.4) months. Compared with TARE, risk of death was lower with TACE (HR [95% CI] 0.82 [0.69-0.97]; P = 0.0242], non-significant in missingness sensitivity analysis) and higher with TAE (HR [95% CI] 1.25 [1.05-1.49]; P = 0.0135]).
TARE was the most common initial embolization therapy and its use increased over time. Time to first follow-up treatment or death was relatively short. Future studies are needed to identify optimal treatment approaches.
PMID:
42895274
Bibliographic data and abstract were imported from PubMed on 19 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 21
- Comments 0